Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if OMER is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
21 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 20 days ago
Red flags: 1
171 filers reported a long position in OMER for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| BlackRock, Inc. | $57.5M | 6M | +13.8% |
| INGALLS & SNYDER LLC | $34.8M | 3.7M | +2.8% |
| UBS Group AG | $29.9M | 3.1M | +34.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.2M | 3.1M | +3% |
| STATE STREET CORP | $22.1M | 2.3M | +20.9% |
| GEODE CAPITAL MANAGEMENT, LLC | $18.2M | 1.9M | +9.3% |
| STIFEL FINANCIAL CORP | $17.5M | 1.8M | +0.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $9.2M | 962.8K | +34% |
| Invesco Ltd. | $7.1M | 751.8K | +316.2% |
| NORTHERN TRUST CORP | $6.9M | 727.3K | +29% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.